Side-by-side · Research reference
PNC-27vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED18/41 cited
BHuman-MechanisticAUTO-DRAFTED12/39 cited
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
PNC-27
Semax
Primary target
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
N/A — cytotoxic mechanism, not signaling modulation
—
Origin
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
PNC-27
Semax
Clinical status
Pre-clinical only — no human trials
In vitro and animal model data only.
—
In vitro concentrations
10–100 μM range
Effective concentrations in cell culture studies.
—
Shorter analogue
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
—
Frequency
—
2–3× per day during cognitive demand
Lower / starter dose
—
100 mcg / dose
Duration
—
10–14 day cycles, repeated PRN
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon
Half-life
—
Short plasma; CNS effect lasts ~3–6 hr
03Metabolic / Fat Loss Evidence
Parameter
PNC-27
Semax
Fat loss mechanism
None — cytotoxic anticancer agent
—
04Side Effects & Safety
Parameter
PNC-27
Semax
Human safety data
None available — no human trials conducted
—
Normal cell selectivity
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
—
Cancer cell specificity
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
—
Mitochondrial effects
Secondary mitochondrial membrane disruption in cancer cells
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid
Absolute Contraindications
PNC-27
- ·Human use — no clinical trials or safety data
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
PNC-27
—Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
PNC-27
Semax
1. Pre-clinical status
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Cell culture protocols
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Fluorescent labeling studies
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
Morning + early afternoon. Avoid evening (sleep disruption).
4. Membrane HDM-2 requirement
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
Refrigerate after reconstitution; light-protected.
5. Caveat
—
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
PNC-27
— no documented stacks
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation